Impaired FGF–19 release and hepatic FGF–19 resistance in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD)

Aims: FGF–19, a novel intestinal hormone, is secreted in the terminal ileum postprandially in response to bile salts. NAFLD is common in obesity, but the molecular mechanisms of NAFLD in non-obese patients remain yet to be defined. FGF–19 could possibly play a beneficial role in NAFLD. The aim of our study was to compare FGF–19 serum concentrations and hepatic response to this enterokine in overweight and obese NAFLD patients as well as healthy volunteers after an oral fat challenge. Patients and methods: In total, we recruited 14 overweight NAFLD patients, 12 obese NAFLD individuals, and 16 healthy controls. NA…